The varying faces of IL-6: From cardiac protection to cardiac failure.

[1]  S. Rose-John,et al.  Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. , 2013, Arthritis and rheumatism.

[2]  A. Hofman,et al.  Interleukin-6 receptor pathways in abdominal aortic aneurysm , 2012, European heart journal.

[3]  C. Wouters,et al.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[4]  A. Quintana,et al.  Interleukin-6, a Major Cytokine in the Central Nervous System , 2012, International journal of biological sciences.

[5]  S. Humphries,et al.  Effects of genetic variation on chromatin structure and the transcriptional machinery: analysis of the IL6 gene locus , 2012, Genes and Immunity.

[6]  S. Boekholdt,et al.  The interleukin-6 pathway and atherosclerosis , 2012, The Lancet.

[7]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[8]  Mark Woodward,et al.  Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .

[9]  Interleukin-6 Receptor Mendelian Randomisation Analysis , 2012 .

[10]  H. Drexler,et al.  Continuous Glycoprotein-130-Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction , 2010, Circulation.

[11]  P. Galle,et al.  Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus , 2010, The Journal of Rheumatology.

[12]  R. Frausto,et al.  Site-Specific Production of IL-6 in the Central Nervous System Retargets and Enhances the Inflammatory Response in Experimental Autoimmune Encephalomyelitis1 , 2009, The Journal of Immunology.

[13]  S. Humphries,et al.  Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. , 2008, Clinical chemistry.

[14]  S. Humphries,et al.  Identification of a novel regulatory region in the interleukin-6 gene promoter. , 2008, Cytokine.

[15]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[16]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[17]  D. Hilfiker-Kleiner,et al.  Role of gp130‐mediated signalling pathways in the heart and its impact on potential therapeutic aspects , 2008, British journal of pharmacology.

[18]  N. Rose,et al.  Pathogenesis of myocarditis and dilated cardiomyopathy. , 2008, Advances in immunology.

[19]  J. Morales-Montor,et al.  IL-6 KO MICE DEVELOP EXPERIMENTAL AMOEBIC LIVER INFECTION WITH EOSINOPHILIA , 2007, The Journal of parasitology.

[20]  M. Fortuño,et al.  Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? , 2007, Cardiovascular research.

[21]  D. Hilfiker-Kleiner,et al.  Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis , 2007, Basic Research in Cardiology.

[22]  Meijing Wang,et al.  JAK/STAT/SOCS SIGNALING CIRCUITS AND ASSOCIATED CYTOKINE-MEDIATED INFLAMMATION AND HYPERTROPHY IN THE HEART , 2006, Shock.

[23]  N. Frangogiannis.  Targeting the inflammatory response in healing myocardial infarcts. , 2006, Current medicinal chemistry.

[24]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[25]  G. H. Thoresen,et al.  Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure , 2006, Diabetologia.

[26]  R. D. Hatton,et al.  Transforming growth factor-beta induces development of the T(H)17 lineage. , 2006, Nature.

[27]  M. Duchen,et al.  IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. , 2006, Cardiovascular research.

[28]  Simon A. Jones,et al.  Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.

[29]  C. Fielding,et al.  IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Kohanawa,et al.  Endogenous Interleukin-6 Plays a Crucial Protective Role in Streptococcal Toxic Shock Syndrome via Suppression of Tumor Necrosis Factor Alpha Production , 2005, Infection and Immunity.

[31]  J. Scheller,et al.  IL-6 transsignaling: the in vivo consequences. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[32]  Tsuyoshi Onogawa.  Local delivery of soluble interleukin-6 receptors to improve the outcome of alpha-toxin producing Staphylococcus aureus infection in mice. , 2005, Immunobiology.

[33]  P. Woo,et al.  Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[34]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[35]  S. Prabhu.  Cytokine-Induced Modulation of Cardiac Function , 2004, Circulation research.

[36]  S. Ahnve,et al.  IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. , 2004, European journal of internal medicine.

[37]  I. Chaudry,et al.  Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function. , 2004, American journal of physiology. Heart and circulatory physiology.

[38]  S. Rose-John,et al.  Inhibition of T Cell Apoptosis in the Aqueous Humor of Patients with Uveitis by IL-6/Soluble IL-6 Receptor trans-Signaling , 2004, The Journal of Immunology.

[39]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[40]  B. Beutler,et al.  The interface between innate and adaptive immunity , 2004, Nature Immunology.

[41]  R. Bolli,et al.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. , 2004, Cardiovascular research.

[42]  Y. Fujio,et al.  Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure , 2004, Heart and Vessels.

[43]  S. Hegde,et al.  Novel immunosuppressive properties of interleukin‐6 in dendritic cells: inhibition of NF‐κB binding activity and CCR7 expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[45]  Scott R. Presnell,et al.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.

[46]  R. DeMatteo,et al.  Increased and Long-Term Generation of Dendritic Cells with Reduced Function from IL-6-Deficient Bone Marrow1 , 2004, The Journal of Immunology.

[47]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[48]  T. S. Wilkinson,et al.  Differential Regulation of Neutrophil-Activating Chemokines by IL-6 and Its Soluble Receptor Isoforms1 , 2004, The Journal of Immunology.

[49]  David Perret,et al.  Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[51]  Y. Mándi,et al.  Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. , 2004, European cytokine network.

[52]  T. Mcclanahan,et al.  WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27 , 2004, The Journal of Immunology.

[53]  H. Drexler,et al.  The Role of Interleukin-6 in the Failing Heart , 2001, Heart Failure Reviews.

[54]  P. Wallace,et al.  Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. , 2004, Immunity.

[55]  T. Kishimoto,et al.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody , 2004, Springer Seminars in Immunopathology.

[56]  S. Fisher,et al.  The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. , 2003, Arthritis and rheumatism.

[57]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[58]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[59]  K. Hagihara,et al.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[60]  N. Mukaida,et al.  Essential involvement of IL‐6 in the skin wound‐healing process as evidenced by delayed wound healing in IL‐6‐deficient mice , 2003, Journal of leukocyte biology.

[61]  R. Kennedy,et al.  JAK2/STAT3, Not ERK1/2, Mediates Interleukin-6-induced Activation of Inducible Nitric-oxide Synthase and Decrease in Contractility of Adult Ventricular Myocytes* , 2003, The Journal of Biological Chemistry.

[62]  S. Rose-John,et al.  Transcriptional profiling identifies Id2 function in dendritic cell development , 2003, Nature Immunology.

[63]  A. Lichtenberg,et al.  Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy , 2003, Circulation.

[64]  S. Marsch,et al.  Interleukin-6–Deficient Mice Resist Development of Autoimmune Myocarditis Associated With Impaired Upregulation of Complement C3 , 2003, Circulation.

[65]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[66]  A. Mantovani,et al.  IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. , 2003, Trends in immunology.

[67]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[68]  K. Kallen.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. , 2002, Biochimica et biophysica acta.

[69]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[70]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[71]  J. Ross,et al.  Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. , 2001, The Journal of clinical investigation.

[72]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[73]  J. Miyazaki,et al.  Tissue-Specific Autoregulation of thestat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T Cells , 2001, Molecular and Cellular Biology.

[74]  J. Pepper,et al.  Quantitative Myocardial Cytokine Expression and Activation of the Apoptotic Pathway in Patients Who Require Left Ventricular Assist Devices , 2001, Circulation.

[75]  P. Gabriele,et al.  Activation of the cardiac interleukin‐6 system in advanced heart failure , 2001 .

[76]  T. S. Wilkinson,et al.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.

[77]  Cindy L. Miller,et al.  Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Simon A. Jones,et al.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  S. Rose-John,et al.  Coordination of interleukin-6 biology by membrane bound and soluble receptors. , 2001, Advances in experimental medicine and biology.

[80]  H. Scheld,et al.  Activation of the cardiac interleukin-6 system in advanced heart failure. , 2001, European journal of heart failure.

[81]  J. Banchereau,et al.  IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.

[82]  R. Holubkov,et al.  Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[83]  T. Luedde,et al.  Interleukin 6 and liver regeneration , 2000, Gut.

[84]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[85]  P. Marrack,et al.  Activation-Induced Inhibition of Interleukin 6–Mediated T Cell Survival and Signal Transducer and Activator of Transcription 1 Signaling , 2000, The Journal of experimental medicine.

[86]  Kishimoto,et al.  Cytokines and their receptors in cardiovascular diseases — role of gp130 signalling pathway in cardiac myocyte growth and maintenance , 2000, International journal of experimental pathology.

[87]  M. Okabe,et al.  Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Y. Shima,et al.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.

[89]  M. Baiocchi,et al.  Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. , 1999, Cytokine.

[90]  S. Straus,et al.  Lack of Interleukin-6 (IL-6) Enhances Susceptibility to Infection but Does Not Alter Latency or Reactivation of Herpes Simplex Virus Type 1 in IL-6 Knockout Mice , 1999, Journal of Virology.

[91]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[92]  M. Entman,et al.  Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. , 1999, Circulation.

[93]  D. H. Mitchell,et al.  Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. , 1999, Circulation.

[94]  大島 至郎.  Interleukin 6 plays a key role in the development of antigen-induced arthritis , 1999 .

[95]  B. Hilliard,et al.  IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. , 1998, Journal of immunology.

[96]  P. Heinrich,et al.  A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. , 1998, Cytokine.

[97]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[98]  H. Robenek,et al.  Left-Ventricular Expression of lnterleukin-6 Messenger-RNA Higher in Idiopathic Dilated Than in Ischemic Cardiomyopathy , 1998, The Thoracic and cardiovascular surgeon.

[99]  A. Matsumori,et al.  Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. , 1998, Circulation.

[100]  Y. Ohsugi,et al.  IL‐6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice , 1998, Clinical and experimental immunology.

[101]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[102]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[103]  T. Robak,et al.  Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. , 1998, Mediators of inflammation.

[104]  G. Zimmerman,et al.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. , 1997, The Journal of clinical investigation.

[105]  T. Vischer,et al.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.

[106]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[107]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[108]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[109]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[110]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[111]  B. McManus,et al.  Modification of viral myocarditis in mice by interleukin-6. , 1996, Circulation research.

[112]  J. Heath,et al.  Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy , 1996, The Journal of Biological Chemistry.

[113]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[114]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[115]  M. Entman,et al.  Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. , 1995, Circulation.

[116]  T. Kishimoto,et al.  Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[117]  W. Wood,et al.  Cardiotrophin-1 , 1995, The Journal of Biological Chemistry.

[118]  A. Ogata,et al.  Hypoxic stress induces cardiac myocyte-derived interleukin-6. , 1995, Circulation.

[119]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[120]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[121]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[122]  M. Tsang,et al.  Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. , 1993, Journal of immunology.

[123]  P. Heinrich,et al.  Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. , 1992, Journal of immunology.

[124]  B. Modrell,et al.  Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. , 1992, The Journal of biological chemistry.

[125]  David J. Anderson,et al.  CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130 , 1992, Cell.

[126]  U. Ikeda,et al.  Serum interleukin 6 levels become elevated in acute myocardial infarction. , 1992, Journal of molecular and cellular cardiology.

[127]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[128]  R. Kyle,et al.  Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. , 1992, Cytokine.

[129]  D. Remick,et al.  Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. , 1991, The American journal of pathology.

[130]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[131]  S. Akira,et al.  A nuclear factor for IL‐6 expression (NF‐IL6) is a member of a C/EBP family. , 1990, The EMBO journal.

[132]  M. Jourdan,et al.  Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. , 1990, Arthritis and rheumatism.

[133]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[134]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.

[135]  T. Hirano,et al.  Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.

[136]  T. Taniguchi,et al.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.

[137]  N. Smukler.  Treatment of rheumatoid arthritis. , 1974, Delaware medical journal.